Get the Stockscreener App
7.99
0.37%
-0.03
Amicus Therapeutics Inc stock is traded at $7.99, with a volume of 5.46M.
It is down -0.37% in the last 24 hours and up +14.31% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$8.02
Open:
$8.08
24h Volume:
5.46M
Relative Volume:
1.19
Market Cap:
$2.46B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-23.50
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+5.27%
1M Performance:
+14.31%
6M Performance:
-12.68%
1Y Performance:
-31.65%
1-Day Range:
$7.99
$8.19
1-Week Range:
$7.605
$8.19
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
7.99 | 2.47B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Trexquant Investment LP Trims Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Redmile Group LLC Has $77.80 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Banque Transatlantique SA Takes $1.26 Million Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Palo Alto Investors LP Sells 317,477 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. $FOLD Shares Bought by PDT Partners LLC - MarketBeat
Rafferty Asset Management LLC Trims Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Can Amicus Therapeutics Inc. outperform under higher oil pricesPrice Action & Expert-Curated Trade Recommendations - خودرو بانک
Ranking Amicus Therapeutics Inc. among high performing stocks via toolsWeekly Investment Recap & Advanced Technical Signal Analysis - Newser
What analysts say about Amicus Therapeutics Inc. stockWeekly Profit Recap & Verified Chart Pattern Trade Signals - خودرو بانک
Is Amicus Therapeutics Inc. a candidate for recovery playPortfolio Return Summary & AI Driven Stock Reports - Newser
Can a trend reversal in Amicus Therapeutics Inc. lead to recoveryJuly 2025 Update & Safe Capital Allocation Plans - Newser
Amicus Therapeutics Inc. stock momentum explained2025 Market Sentiment & Growth Focused Investment Plans - Newser
How to read the order book for Amicus Therapeutics Inc.2025 Stock Rankings & Daily Market Momentum Tracking - Newser
Is this a good reentry point in Amicus Therapeutics Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - Newser
Using economic indicators to assess Amicus Therapeutics Inc. potentialJuly 2025 Recap & Pattern Based Trade Signal System - Newser
Evaluating Amicus Therapeutics Inc. with trendline analysisMarket Performance Recap & Reliable Price Breakout Alerts - Newser
Is Amicus Therapeutics Inc. reversing from oversold territory2025 Macro Impact & Verified Momentum Watchlists - Newser
Quantitative breakdown of Amicus Therapeutics Inc. recent moveMarket Rally & Scalable Portfolio Growth Methods - Newser
Kodai Capital Management LP Purchases New Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
683 Capital Management LLC Acquires Shares of 275,000 Amicus Therapeutics, Inc. $FOLD - MarketBeat
Vestal Point Capital LP Grows Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Dark Forest Capital Management LP Buys 588,689 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Using AI based signals to follow Amicus Therapeutics Inc.Portfolio Performance Report & AI Forecasted Entry/Exit Points - Newser
Wall Street Zen Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold - MarketBeat
Should you hold or exit Amicus Therapeutics Inc. now2025 Volatility Report & Short-Term Trading Alerts - Newser
Russell Investments Group Ltd. Increases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Real time social sentiment graph for Amicus Therapeutics Inc.2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Reversal indicators forming on Amicus Therapeutics Inc. stockJuly 2025 Drop Watch & Reliable Price Breakout Alerts - Newser
Using Python tools to backtest Amicus Therapeutics Inc. strategiesCEO Change & Reliable Price Action Trade Plans - Newser
Earnings visualization tools for Amicus Therapeutics Inc.2025 AllTime Highs & Verified Short-Term Plans - Newser
How to build a custom watchlist for Amicus Therapeutics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser
Applying Wyckoff theory to Amicus Therapeutics Inc. stockJuly 2025 Levels & Safe Capital Investment Plans - Newser
Is Amicus Therapeutics Inc. stock a buy or sell getLinesFromResByArray error: size == 0 - 머스트 뉴스
Has Amicus Therapeutics Inc. found a price floorMarket Risk Analysis & Low Risk High Reward Trade Ideas - Newser
What makes Amicus Therapeutics Inc. stock price move sharplyJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - Newser
Analyzing Amicus Therapeutics Inc. with risk reward ratio chartsWeekly Market Outlook & Target Return Focused Stock Picks - Newser
Price Channel Expanding on Amicus Therapeutics Inc.’s Chart getLinesFromResByArray error: size == 0 - thegnnews.com
Exit strategy if you’re trapped in Amicus Therapeutics Inc.July 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
Price action breakdown for Amicus Therapeutics Inc.Trend Reversal & Daily Stock Momentum Reports - Newser
Risk adjusted return profile for Amicus Therapeutics Inc. analyzedGlobal Markets & Stock Timing and Entry Methods - Newser
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Amicus Therapeutics Inc. a play on infrastructure spendingWeekly Profit Report & AI Enhanced Execution Alerts - خودرو بانک
Is Amicus Therapeutics Inc. subject to activist investor interest2025 Top Gainers & Precise Entry and Exit Recommendations - خودرو بانک
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):